USPTO 2015–2025 USPTO PatentsView US Corporation

Nevakar Injectables Inc.

USPTO PatentsView assignee record - 11 granted patents across 4 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

RSS updates for this company

The verdict

According to USPTO PatentsView, Nevakar ranks #24,870 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 4 technology areas.

#24,870
of 49,997 US assignees by volume
Top 22%
by Innovation Score (45.8/100)
16.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R24870 · US Corporation #24,870 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 11 grants
  • MID-PACK #24,870/49,997
  • PHOTO-FINISH Neopad
  • CPC-NARROW A61K · 4 areas
  • INNOV-PAR 45.8/100
  • CLAIMS-RICH 16.8 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2021–2025 · 5y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Neopad Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Nevakar’s 45.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Nevakar

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Nevakar's Innovation Score is 45.8/100 (top 22% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Nevakar?

Each dot is one of Nevakar’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Nevakar’s own 16.8 claims/patent is ABOVE the 16.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Nevakar vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 10.910.91111.1 510152025 Granted patents (volume) Avg claims / patent Neopad Inc. - 11, 21.18NeopadNESTLÉ Skin Health SA - 11, 14.64NestlÉ Skin HealthNetsweeper (BARBADOS) Inc. - 11, 22Netsweeper (Barba…Neumayer Tekfor Engineering GMBH - 11, 7.64Neumayer Tekfor E…NEW Concepts Development Corporation - 11, 9.45NEW Concepts Deve…Nextteq LLC - 11, 16NextteqNexus Spine, LLC - 11, 18.55Nexus SpineNExT-e Solutions Inc. - 11, 16.45Next-e SolutionsNevakar Injectables Inc. - 11, 16.82Nevakar Injectabl…
Nevakar vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Nevakar's grants concentrate

Nevakar Injectables Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2023 (4 grants) versus a trough of 1 in 2021. By volume, Nevakar sits between Neopad Inc. and NExT-e Solutions Inc..

Nevakar's three-year grant acceleration

Nevakar Injectables Inc. shows 8 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Nevakar's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Nevakar holds 11 patents at rank #24,846, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Nevakar

By rank, the assignees closest to #24,846 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Nevakar's primary technology class.

Nevakar's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 22% higher than 78% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 20212022202320242025 2
USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table
Nevakar Injectables Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2021 1 9.1%
2022 2 18.2%
2023 4 36.4%
2024 2 18.2%
2025partial year 2 18.2%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Nevakar Injectables Inc.'s patent record in context - here's where to go next.

  • Nevakar Injectables Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
  • Ranked #24,870 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Nevakar Injectables Inc. against Neopad Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 45.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.